Israeli - Kiebrania - Ministry of Health

teva israel ltd - calcium folinate - טבליה - calcium folinate 16.2 mg - detoxifying agents for antineoplastic treatment - counteracts the action of folic acid antagonists. improves blood picture in megaloblastic anemias due to folate deficiency. as leucovorin- fluorouracil combination chemotherapy in cancer.

Israeli - Kiebrania - Ministry of Health

rekah pharmaceutical industry ltd, israel - calcium citrate; ferrous citrate - טבליה - calcium citrate 249 mg; ferrous citrate 246 mg - iron bivalent, oral preparations - prevention and treatment of iron-deficiency anemia.

Israeli - Kiebrania - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g; calcium chloride 0.1838 g; glucose as monohydrate 16.5 g; lactic acid as sodium 3.925 g; sodium chloride 5.786 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

Israeli - Kiebrania - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - sodium chloride 5.786 g; lactic acid as sodium 3.925 g; glucose as monohydrate 46.75 g; calcium chloride 0.1838 g; magnesium chloride 0.1017 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

Israeli - Kiebrania - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g; glucose as monohydrate 25 g; calcium chloride 0.1838 g; sodium chloride 5.786 g; lactic acid as sodium 3.925 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

Israeli - Kiebrania - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g/l; sodium chloride 5.786 g/l; calcium chloride 0.2573 g/l; glucose as monohydrate 16.5 g/l; lactic acid as sodium 3.925 g/l - combinations of electrolytes - combinations of electrolytes - for patients with (decompensated) chronic renal failure being maintained on peritoneal dialysis.

Israeli - Kiebrania - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - lactic acid as sodium 3.925 g/l; calcium chloride 0.2573 g/l; glucose as monohydrate 46.75 g/l; magnesium chloride 0.1017 g/l; sodium chloride 5.786 g/l - combinations of electrolytes - combinations of electrolytes - for patients with (decompensated) chronic renal failure being maintained on peritoneal dialysis.

Israeli - Kiebrania - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 40 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israeli - Kiebrania - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israeli - Kiebrania - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190